Farglitazar
Systematic (IUPAC) name
N-(o-benzoylphenyl)-O-[2-(5-methyl- 2-phenyl-4-oxazolyl)ethyl]-L-tyrosine
Clinical data
Pregnancy
category
  • N/A
Legal status
  • Investigational
Identifiers
CAS Registry Number  N
ATC code None
PubChem CID:
IUPHAR/BPS
ChemSpider  N
UNII  YesY
ChEMBL  N
Chemical data
Formula C34H30N2O5
Molecular mass 546.612 g/mol
 N   

Farglitazar is a peroxisome proliferator-activated receptor agonist which is being developed by GlaxoSmithKline for the treatment of hepatic fibrosis. It is currently in phase II clinical trials.

References